ABBOTINDIA

Financial performance

Financial Performance Abbott India reported an 11–12% year-on-year revenue growth in the June 2025 quarter, with profits rising by more than 11%. In the March 2025 quarter, profit surged by nearly 28% on strong demand for gastrointestinal, anti-infective, cardiovascular, and diabetes-related medicines. The company remains debt-free, has maintained strong margins, and continues to deliver consistent profit growth over the last five years. Over the past year, the stock has seen volatility, at one point falling around 20% from its highs, but it remains a strong dividend-paying company. Leadership and Governance Swati Dalal stepped down as Managing Director in June 2025. Kartik Rajendran has been appointed as the new Managing Director. Maithilee Mistry took charge as Chief Financial Officer in May 2025. The company held its 81st Annual General Meeting in August 2025. Dividends and Shareholder Updates A final dividend of ₹475 per share was declared in May 2025, continuing Abbott India’s tradition of high dividend payouts. Products, Research and Operations Abbott launched advanced heart-care devices like the TactiFlex ablation catheter and the Navitor Vision heart valve in India. A new pneumococcal conjugate vaccine for children was introduced to strengthen its vaccine portfolio. The company rolled out a lab-based blood test for concussion evaluation. A partnership with MSD was announced to distribute innovative oral anti-diabetic medicines in India. Global Parent Updates Abbott Laboratories, the global parent, settled patent disputes with DexCom related to glucose monitoring devices, ensuring smoother operations in the diabetes care segment worldwide.